Viva Biotech provides one-stop services ranging from early-stage structure-based drug R&D to commercial manufacturing for global biopharmaceutical innovators. Established in 2008, Viva Biotech offers drug discovery expertise, integrating dedicated experts, cutting-edge technology platforms, and state-of-the-art equipment.

Viva Biotech

Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial manufacturing to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX, AIDD/CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. The experienced chemistry team, led by senior medicinal chemists and drug discovery biologists, provides services for drug design, medicinal chemistry (hit to lead and lead optimization), custom synthesis, chemical analysis and purification, kilogram scale-up, peptide synthesis and corresponding bioassays. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.

Totient

Temasek Holdings

Danming Fund

Honghui Fund

Beida Biomedical Industry Fund

Viva Ventures Biotech Fund

Ming Bioventures

Xiamen Changrong Investment Management

Yingqi Investment

JMCR Partners

Viva Biotech 

At Viva Biotech, we believe in #innovation. That's why our newly finished headquarters, with 40,000 square meters, features new, state-of-the-art facilities and laboratories. We strive to be the best partner in your #drugdiscovery, development, and production processes.

Are you curious about protein structure services at Viva Biotech? At Viva Biotech, experienced experts collaborate to provide comprehensive discovery biology services and expedite drug discovery.

Delve into the details: https://lnkd.in/gZmcRJac

#proteinstructure #cro #cdmo #sbdd #drugdiscoveryservices #drugdevelopment

We are honored that our subsidiary, Langhua Pharmaceutical, has received the API Development & Innovation Award at the CPHI China 2024. This recognition highlights Viva Biotech’s excellence in CDMO services. 

Learn more: https://lnkd.in/gnApkmCC

#CPHIChina #cdmo #API #vivabiotech #langhuapharmaceutical #PharmaInnovation #cro

Are you working with PROTACs? 

Elevate your drug discovery with Viva Biotech’s one-stop PROTAC services. Click on the image to explore our high-quality, efficient, and reliable support.

📢 Don't miss our upcoming PROTAC webinar! Register now to be part of this exciting event: https://lnkd.in/eAMH24CM

#protac #protacs #medchem #proteindegradation #undruggabletargets #cro #cdmo #vivabiotech #drugdiscovery #drugdevelopment

Join us for an enlightening webinar, this session will delve into cutting-edge strategies in PROTACs. Hear from leading experts Michael R.，David Taddei, Jean-Marc Garnier as they unveil their insights into Linkerology, case studies in PROTAC development, and structure-guided optimization strategies. 

Mark your calendars, the date is set! Register now and be part of the revolution in drug discovery!

Here is the registration link: https://lnkd.in/eAMH24CM

#PROTAC #PROTACs #medchem #proteindegradationresearch #proteindegradationstrategy #proteindegradation #molecularglues #PROTACLinkers #compchem #drugdevelopment  #drugdiscovery #cro #cdmo #BiotechInnovation

We're delighted to share that our V-DEL platform poster presentation at SABPA the 8th Annual Frontiers in Therapeutics and Diagnostics (FTD) was awarded the “Excellence Award” last month! This recognition marks the first time we've showcased our DEL platform poster at a conference and underscores our commitment to innovative technology. Additionally, our team had the pleasure of hosting a Lunch and Learn workshop at the FTD Forum in San Diego. Our experts, Yinghong Gao, highlighted our cutting-edge V-DEL platform as part of our comprehensive, one-stop drug discovery platforms. Meanwhile, Jianguo Ma showcased Zhejiang Langhua Pharmaceutical Co., Ltd.'s CDMO services, capturing significant attention.
 
Curious to learn more about our hit discovery platforms? Reach out to us at marketing@vivabiotech.com for further details. At Viva Biotech, we're dedicated to accelerating your drug discovery journey, from SBDD to commercial manufacturing.

#cro #cdmo #del #drugdiscovery #sbdd #biotech #FTD #sabpa #drugdevelopment #bioresearch #biopharmaceuticals

Euro

CrUX Dataset

CrUX Top 10m

Venture Partner

Guanghui Hu

Han Dai

CBO and Head of Investment

Cheney Mao

Founder, Chairman, CEO

DTx Pharma is a biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease.

Nerio Therapeutics is a biotechnology company focused on the life sciences sector.

Focus-X Therapeutics is a preclinical-stage biotechnology company focused on the radiopharmaceutical pipeline.

Investors Active in Ontario

Seed Stage Investors with Investments in Greater New York Area

Investors Active in China (Top 10K)

Asia Early Stage Venture Investors

Viva BioInnovator (VBI) is the specialized investment and incubation arm of Viva Biotech Holdings. We focus on the initial creation and development of biotech startups across all indications and drug types. During the early stages of drug discovery, we can nurture and accelerate a startup's growth from idea to clinical program. 

VBI's unique investment and incubation model started out of necessity in 2014. Our roots are in drug discovery services, where we operate world-leading and proprietary drug discovery platforms. While serving big pharma customers from around the globe, we came to realize the huge demand from many entrepreneurs who have great ideas but cannot receive funding to advance their plan due to lack of data. We saw the value in many of these innovative ideas and provided our CRO drug discovery services, operational support, and monetary backing to help these creative scientists embark on the "0 to 1"​ transformation. This spark launched our "equity for service (EFS)"​ investment and incubation model. 

VBI is based in Shanghai, with an office in Boston and personnel in California. As of early 2019, VBI has invested in over 30 companies out of the hundreds of proposals submitted for review and we plan to invest at a rapid pace in the years to come. The majority of our current portfolio companies are US based, but we are open to proposals globally and are excited to see new ideas that fit our investment strategy. 

If you would like to learn more about us, please visit: www.vivabioinnovator.com 
Or send an email to innovation@vivabiotech.com 

If you would like to learn more about our parent company, Viva Biotech, please visit: www.vivabiotech.com

news impact assignment basic	general
public peers	general	Aug 10, 2024 7:39 AM	0a7272f1
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	a9518019
crunchbase profile	general	Nov 22, 2024 3:31 PM	231154a8
li profile	general	Aug 10, 2024 7:39 AM	2cdcfbee
translate crunchbase fundingrounds	general	Nov 22, 2024 6:56 PM	ab31cc38
peers	general	Aug 10, 2024 7:39 AM	65784e7e
news basic	general	Aug 10, 2024 7:39 AM	a7e7df82
bundesanzeiger	filings
financials download nd	financials
private financials	financials

VIVA

COM:VIVABIOTECH

Viva Biotech